Mélissa Chénard

An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies

Jennifer O’Neil, Yair Benita, Igor Feldman et al. · Molecular Cancer Therapeutics · 2016 · 410 citations

Drug Target, Combination Drug Therapy, Tumor Biology +17

Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression

Tikvah K. Hayes, Nicole F. Neel, Chaoxin Hu et al. · Cancer Cell · 2015 · 271 citations · Full text

Oncology, Pancreatic Cancer, Long-term Erk Inhibition +10

Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2)

Joey L. Methot, Prasun K. Chakravarty, Mélissa Chénard et al. · Bioorganic & Medicinal Chemistry Letters · 2007 · 185 citations · Full text

Histone Modifications, Chromatin, Medicinal Chemistry +10

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors

Andrey Loboda, Michael Nebozhyn, Rich A. Klinghoffer et al. · BMC Medical Genomics · 2010 · 151 citations · Full text

Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2)

David J. Witter, Paul E. Harrington, Kevin J. Wilson et al. · Bioorganic & Medicinal Chemistry Letters · 2007 · 94 citations · Full text

Biaryl Selective Hdac1, Molecular Pharmacology, Medicinal Chemistry +7